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Abstract
Glioblastoma multiforme, an aggressive malignant tumor, continues to be amongst the
most fatal disorders in medicine despite many therapeutic techniques and drug discoveries.
Malignant brain tumor cells’ ability to invade surrounding brain parenchyma is the main reason
for treatment failure and recurrence. Traditional chemotherapy methods have found difficulty
accessing the brain due to the blood-brain barrier, while irradiation techniques cause damaging
effects on normal regions of the brain. New forms of gene therapy have been found to
eliminate tumor cells, while sparing healthy brain tissue; however, with no efficient delivery
mechanism gene therapy has been unable to access a large amount of tumor cells to eliminate
the tumor mass and prevent the likelihood of recurrence. Local delivery of gene therapy has
introduced a new method that looks to solve this problem, by delivering therapy directly to the
brain tissue. One method of local delivery is convection-enhanced delivery (CED) of poly(lacticco-glycolic acid (PLGA) nanoparticles, a biocompatible polymer material. Using a catheter and
pump, this intracranial drug delivery method allows for drug-loaded nanoparticles to be
released directly into brain tissue in a bulk flow of fluid. This method bypasses the blood-brain
barrier and has a large distribution volume which has direct access to the tumor mass.
The efficacy of CED of siRNA nanoparticles on suppressing gene expression in tumor
cells was studied in both in vitro experiments and in vivo rat models. Fisher 344 rats were used
as the animal model and 9L gliosarcoma cells, a highly aggressive malignant tumor, labeled with
enhanced green fluorescent protein (EGFP) were the tumor source. Small interfering RNA
targeting the EGFP gene (siEGFP) were encapsulated into PLGA nanoparticles and used as a
gene therapy. Our study shows that siEGFP nanoparticles are capable of causing in vitro and in
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vivo gene expression reductions of up to 50 and 60%, respectively. When 9L cells were exposed
to small interfering epidermal growth factor receptor (siEGFR), which targets the EGFR gene, in
vitro growth suppression was observed that reduced 9L cell growth by 89% compared to the
untreated control. These gene knockdown results shown in this thesis suggest that siRNAloaded PLGA nanoparticles provide a great potential means for treating tumors.
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Introduction
Each year in the United States nearly 16,000 people are diagnosed with primary brain
tumors. Sixty percent of the brain tumors diagnosed in the United States are gliomas. Gliomas
are a heterogenous mix of neoplastic astrocytes.

Amongst these gliomas, glioblastoma

multiforme (GBM) is the most common malignant glial tumor accounting for 12-15% of all
intracranial neoplasms. This neoplasm is often found in the subcortical white matter of the
cerebral hemispheres. In the United States and Europe, the incidence of GBM is 2-3 cases per
100,000 people (1).
There are two forms of Glioblastoma multiforme, primary and secondary. Primary GBM
is more prevalent (60% of cases) and consists of a de novo neoplasm that has no
histopathologic evidence of a precursor lesion. This type of lesion tends to present in patients
over 50 years old. Secondary glioblastoma multiforme often occurs in patients under 45 years
old and forms from a slow progression of either a low grade astrocytoma or anaplastic
astrocytoma. This progression can take anywhere from one to ten years (2).
The etiology of GBM tumors varies widely. Some of the genetic abnormalities seen in
GBM tumors consist of 1) Loss of heterozygosity on the chromosomal arm 10q, 2) mutation in
the tumor suppressor gene p53, 3) mutations in the epidermal growth factor receptor gene,
which controls cell proliferation, 4) overexpression of the MDM2 gene, 5) overexpression of the
platelet-derived growth factor-alpha gene (PDGF-α), which acts as a major growth factor for
glial cells, and 6) mutation of the PTEN gene which encodes a tyrosine phosphatase that turns
off signaling pathways. Other mutations that are present in the most malignant forms of GBM
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tumors are the MMAC1-E1 gene mutation, MAGE-E1 gene mutation, and NRP/B-A nuclearrestricted protein mutation (2).
Mean survival for GBM patients is inversely correlated with age.

Glioblastoma

multiforme is slightly more common in whites and has a male-to-female ratio of 3:2. Without
treatment patients suffering from GBM will die in 3 months. Those undergoing the standard
treatment of surgical resection, radiation therapy, and chemotherapy have a median survival of
9 months, with about 10% percent of these patients surviving for up to two years (1).
Treatment options
Glioblastoma multiforme remains a difficult tumor to cure. Despite what is known
about the gene mutations of the tumor, multiple challenges remain. Current treatment aims at
improving the quality of life of a patient with the standard care consisting of tumor resection
followed by a combination of chemotherapy with temozolamide and radiation therapy.
However these treatments have their limitations.

Poor tumor cell drug uptake, drug

metabolism within the cell, and the degree of tumor cell sensitivity to a drug all limit the
effectiveness of chemotherapies (1). Surgical resection is often limited depending on the
tumor’s location and the eloquence of the brain region. In addition, the infiltrative nature of
GBM tumors causes the majority of resections to be incomplete which allows infiltrative tumor
cells to reform tumor within the near proximity of the resected site (3).
Available chemotherapies have provided modest prolongation of survival and have been
the focus of many laboratories.

Temozolomide, the current standard, has shown some

promise. A phase III randomized study showed that low-dose temozolomide used along with
radiation therapy followed by six additional months of temozolomide showed a statistically
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significant extended survival length of 14.6 months compared to 12.1 months with radiation
therapy alone. Another phase III randomized study looked at the implantation of FDA approved
Gliadel wafers (polymer wafers with carmustine) into the tumor resected area of the brain and
found prolongation of survival of 13.9 months compared to 11.6 months in the control group
that received only radiation therapy (2).
The Blood Brain Barrier and Brain tumor treatment
In addition to tumor insensitivity and invasiveness, many chemotherapies are
unsuccessful at treating central nervous system (CNS) disorders because of their inability to
cross the blood brain barrier (BBB). This is a specialized system of capillary endothelial cells
that creates a semi-permeable barrier that protects the brain from noxious substances while
still transporting essential nutrients to the brain. The BBB is composed of an inner layer of
endothelial cells with tight junctions, a basement membrane, pericytes, and astrocytes. This
serves as both a physical barrier and a biochemical barrier that is able to express peptidases
that aid in effluxing drugs from the endothelial capillary cells back into the blood stream. Small
molecules that are less than 400 Da and have a high lipid solubility are two characteristics that
have been shown to allow for transport across the BBB. Some regions of the CNS, known as
circumventricular organs, provide areas where the BBB is absent and the capillary system
consists of fenestrated endothelial cells. Areas such as the choroid plexus, pineal gland,
neurohypophysis, area postrema are a few examples of this (4).
In order to make chemotherapies effective once introduced into circulation, the BBB
must be accounted for and several methods of drug delivery have had to deal with this issue.
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Intravenous drug delivery allows for the administration of large amounts of drug into
the blood circulation and avoids the first-pass metabolism.

However, intravenous

administration of therapeutic drugs would result in little accumulation of the drug in the brain
as a result of ineffective penetration across the BBB, as well as rapid metabolism of the drug in
the plasma, and non-specific binding to plasma proteins (4).
Intraarterial administration of drugs has also been used as a method to access the brain.
This method allows for a drug to enter brain vasculature prior to entering peripheral tissue
which bypasses first pass metabolism. It is believed that drugs travel arterially into the choroid
plexus epithelium, then are transferred into the cerebral spinal fluid (CSF).

Often BBB

disrupting agents such as bradykinin and mannitol can be used intraarterially to enhance the
delivery of drugs to the brain, however, the amount of drug that reaches the brain is difficult to
determine with this method (4).
The intranasal route allows a drug to reach the brain by traveling through the nasal
mucosa. In this instance, the drug travels from the submucosa of the nose into the CSF. This
method is non-invasive and bypasses first-pass metabolism and the BBB completely. The
permeability of the nasal epithelium allows for the uptake of drugs tranasally into the brain and
allows for the delivery of micro and macromolecules. Intranasal delivery allows for selfadministration of small doses without the need of any modifications of the drug, such as
coupling to a carrier. Limitations of this method include damage and irritation to the nasal
mucosa, rapid clearance of the drug via mucocilia in the nasal cavity, and interruption of drug
transport secondary to nasal congestion (4).
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Another method used to completely bypass the BBB is through direct delivery of the
therapeutics into the CSF of the CNS. This method allows for higher concentrations of drug into
the brain, avoids systemic exposure toxicities, and maintains the drug for a longer period of
time within the brain. This method can produce variable results depending on where the drug
site of puncture is located, rate of drug clearance, CSF production rate, and the drug diffusion
rate (4).
Intraparenchymal delivery allows for drugs to be injected as a bolus or an infusion
through catheters or microparticles. Bolus injection of a drug into the brain causes slow
movement within the parenchyma due to limited diffusion in the brain. Large amounts of drug
must be used in order to overcome diffusion limitations to allow for adequate concentrations
of the drug to be available to the surrounding parenchyma. In an attempt to overcome
diffusion issues, infusion of a drug using convection enhanced delivery (CED) distributes the
drug to a wide area of brain tissue (4).
Convection Enhanced Delivery
CED is a method that was developed to overcome the diffusion limitation posed by the
brain. CED applies an external force to induce fluid convection within the brain. Small
catheters are placed several centimeters into the brain and are used to deliver a therapeutic via
a pump. High pressures are used to produce convective flow. CED provides larger distribution
volumes when compared to bolus injections. It also provides long infusion times and is a viable
method of delivering gene therapy, chemotherapy, and immune therapy. Problems with this
procedure are related to its invasiveness and drug distribution limitations that result from the
anatomical environment. These limits include backflow and occlusions of the catheter as well
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as high intracranial pressures from the catheter infusion. Small air bubbles can form from the
infusion and cause damage to brain tissue.

The distribution of drug delivery is also

unpredictable. The white matter tracks of the brain provide highly conductive routes for the
infused drug. With this high conductivity and the backflow in the catheter, much of the drug
delivered by CED will not be able to diffuse throughout the brain parenchyma. In addition,
perivascular spaces within the brain as well as the wound track of the injection or the space
underneath the scalp can collect the infused drug during delivery shifting it away from its
target.

These factors make it difficult to determine if the infused drug is a consistent

concentration throughout its distributive space and may also lead to edema (3).
A recent phase III clinical study compared Gliadel to CED delivery of IL-13PE38QQR in
patients who had failed conventional treatment for GBM tumors (surgery, radiotherapy, and
chemotherapy). The study showed that there was no significant difference in patient outcome
with the median survival following tumor recurrence with the Gliadel and CED being 36.4 weeks
and 35.3 weeks, respectively (5). A follow up paper suggested that imprecise catheter
placement may have resulted in an absence of benefit in the CED exposed patient population
(6).
Compared to bolus injections, CED maintains drug distribution and concentration over a
longer duration. Alam et al. looked at the delivery of cytosine arabinoside, an antimetabolic
agent used as a chemotherapy, and showed that CED provides for intraparenchymal
concentrations that are 100 times greater than intranasal delivery and 1000 to 10,000 times
greater than intravenous delivery (4).
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Implantable devices that provide controlled release of a drug within the brain are also
used to provide direct drug delivery to the brain.

These implants are made of either

biodegradable or non-biodegradable material and often encapsulate the drug. They are placed
into the brain where they release the drug for a predetermined duration.

One type of

implantable device is the osmotic pump with refillable reservoirs that distributes drugs via a
catheter.
For the purposes of this thesis, most of the focus will be on biodegradable, and more
specifically polymer implants that are often used to deliver drugs to tumors. These devices are
constructed in the form of either wafers or nanoparticles and offer continued release of drugs
from a degrading polymer. (4).
Wafer polymers, such as Gliadel, are polyanhydride wafers that contain the
chemotherapeutic agent carmustine (BCNU). This device has been FDA approved in the U.S. for
implantation for new and recurrent Glioblastoma tumors. Following the resection of a tumor
these wafers can be inserted into the resected tumor cavity where they release the
chemotherapy at a controlled rate that is proportional to the degradation rate of the specific
polymer. The tumor is exposed to 113 times the concentration of BCNU with Gliadel than
would be achieved with systemic administration of the drug (7). The localized chemotherapy
provided by the wafers prevents a patient from being exposed to the high levels of radiation
therapy that can weaken the immune system (3).
Although wafer polymers provide a controlled release system that is capable of
sustained release for long durations of time, local penetration of the drug is often restricted by
diffusion. The drug’s low diffusion coefficient as well as the extracellular matrix (ECM) of the
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brain, which presents small pore sizes, and the local environment of the tumor further limit the
diffusive abilities of a drug. In addition, many drugs have high rates of elimination. The stated
limitations cause a given drug to travel a minimal distance from its starting locus before
degrading. For the wafer polymer, the drug distribution is confined proximally to the wafer
while the invasive tumor cells extend beyond this distance. One way to bypass this issue is by
using a polymer delivery system that is capable of navigating through the pores of the ECM in
order to provide better diffusion throughout the brain (3). Nanoparticles provide a smaller
delivery vector that may be capable of greater distributive properties.
Nanoparticles
Nanoparticles have become a popular mode of drug delivery to tumors in recent years.
With their small size, controlled release capabilities, and the ability to modify the carriers to
target selected molecules and receptors, nanoparticles present a new means for tumor
therapy.

Nanoparticles can be used via direct infusion into the brain or by endcytotic

mechanisms that allow them to cross the BBB (4). They can be either nondegradable or
biodegradable.

The nondegradable nanoparticles function by releasing drug from the

nanoparticle matrix which then diffuses into the brain.

Biodegradable drug release is

determined by the degradation of the polymer matrix in addition to the diffusion of the drug.
Biodegradable polymers can be combined to form copolymers that modify the degradation and
release pattern of the nanoparticle. Properly designed nanoparticles have the capability of
sustained drug delivery for several days to years. Alterations can also be made to the polymer
composition to affect release rate and longevity of a drug. Unlike biodegradable wafers,
nanoparticles have the ability to completely erode and be cleared from the body.

The
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degradation of the nanoparticles occurs via hydrolysis, utilizing the large amounts of water in
the human body. Nanoparticles are also advantageous to their polymer wafer counterparts
because the particles are able to be delivered less invasively to the brain via a burr hole and
catheter (3).
Polymer constructs can be altered in order to maximize the release of a drug. For
example, the popularly used poly[bis(p-carboxyphenoxy)] propane-sebacic acid (p(CPP-SA)) is
hydrolytically unstable when combined with the drug 4-hydroperoxycyclophosphamide (4HC),
however, fatty acid dimer copolymers with 4HC provide the advantage of stability over the
p(CPP-SA).
Another type of biodegradable polymer that has often been used in local drug delivery is
the polylactic-coglycolic acid (PLGA) copolymer, which is a polymer matrix composed of lactide
and glycolide polymers. PLGA is a hydrophobic polymers whose monomer components are
biocompatible.

This biomaterial has been used to make both nanoparticles and wafers and

provides the ability to modify the characteristics of these particles that alter size and drug
release. Studies dealing with the characterization of nanoparticles have shown that smaller
particles, 20nm in diameter or smaller, show more diffusion within the brain than larger
particles, greater than 40nm. Surface characteristics can also play a role in volume distribution.
Mamot et al showed that particles with neutral or negative charge or that are coated with
bovine serum albumin (BSA) or poly(ethylene glycol) (PEG) are able to maximize distribution
volume, whereas positive charge has restricted diffusion. (3)
Combining CED with nanoparticles theoretically improves the delivery of drug to the
brain. The encapsulation of the drug within the nanoparticle prevents drug reflux which
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improves delivery and helps prevent wound dehiscence. Encapsulated drugs can also allow for
shorter infusion times using CED. This would cause smaller volumes of infusates and reduce the
risk of edema and inflammation. However, combining CED and nanoparticles may also present
problems. The polymer nanoparticles have to be large enough to deliver a relevant dose,
however small enough to diffuse sufficiently throughout the parenchyma (3).
Small Interfering RNA nanoparticles
In addition to CED, other modifications can be made to polymer nanoparticles to help
improve therapy. One of these alterations includes using small interfering RNA (siRNA) as the
drug therapeutic. RNA interference is a sequence specific gene silencing application which
utilizes a 21-25 base pair double stranded RNA nucleotide sequence, known as siRNA. The
siRNA are integrated into RNA induced silencing complex (RISC) in the cytosol of the cell. The
RISC complex uses the antisense strand of the siRNA to bind to the complementary messenger
RNA (mRNA) strand in the cell. This initiates the initial cleavage and degradation of the specific
mRNA sequences (8).
When preparing siRNA as a therapeutic for tumors, multiple steps must be taken. First
the siRNA must target mRNA whose downregulation would suppress growth or is integral to the
disease process. The siRNA must then be placed in a delivery complex that is capable of
stability within an in vivo environment. Finally the siRNA complex must be efficiently delivered
to the brain or tumor site in order to effectively knockdown gene expression (8).
Some limitations that are involved with naked siRNA include early extracellular
degradation in the serum, often having a half-life of a few minutes to one hour. Some solutions
that have tried to improve the stability of siRNA include chemical modifications that alter the
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sugar backbone of the siRNA molecule. In addition, polymer or lipid encapsulation have been
shown to protect the siRNA from early degradation. Naked siRNA also has a relatively large
molecular weight of around 13 kDA and an anionic charge, both which makes it impossible to
diffuse freely across the cell membrane. Certain solutions to this problem include conjugating
the siRNA to cell penetrating peptides (CPPs) or cholesterol. Encapsulation of the siRNA with a
polymer will also allow for endocytosis of the siRNA/polymer complex into the cell. (8)
Although siRNA are beneficial for their specificity in targeting genes, other issues with
this type of therapy include nonspecific mRNA binding that can occur through partial mismatch
or binding of the sense strand to the mRNA.

This nonspecific binding may cause interferon

directed inflammation, toxicity to the cell, and unintended effects on the gene target. Chemical
modifications to the siRNA including annealing of the guide strand to an additional strand can
prevent non-specific effects. (8)
The limited success with the delivery of naked siRNA makes it necessary to develop a
delivery vehicle that is capable of transporting and releasing siRNA adequately. Nanoparticles
provide a means of achieving this. Peptides, lipids, and polymers are among some of the
materials that have been used to deliver siRNA and are described below (8).
The smallest type of nanoparticle (about 10nm) are those where the sense strand of the
siRNA is attached to a peptide or small molecule. This modification of the sense strand does
not affect the siRNA’s ability knockdown a gene, since the antisense portion of the siRNA is
what binds to the mRNA. Studies have shown that conjugating siRNA to CPP or PEG have
improved in vivo siRNA transfer (8).
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Larger nanoparticles allow for easier modifications that can enable cell/tissue specific
targeting, longer circulation times, and better prevention of siRNA degradation. Cationic
polymers, ranging from 100-300nm have been shown to form electrostatic interactions
between the positive charges of the polymer and the negatively charged phosphate groups of
the siRNA backbone (8).
Cationic lipid vectors, also ranging from 100-300nm in size, have also shown great
promise with knocking down genes using siRNA. Lipid nanoparticles are believed to have a
weaker electrostatic bond with the siRNA which allows for easier release of the siRNA into the
cytosol. Several lipid vectors have been commercially produced to deliver siRNA to cells. These
include Lipofectamine RNAiMAX and DharmaFECT, as well as others (8).
Both cationic lipids and polymers have the complication of toxicity. This can be avoided
by using a neutral liposome vector, often smaller than 200 nm in size. These nanoparticles
often have hydrophilic cores that contain the siRNA with hydrophobic surfaces that protect the
siRNA from degradation from the surrounding environment. The hydrophobic surface also aids
with internalization of the siRNA through endocytosis or membrane fusion (8).
Other nanoparticles include Hyaluronic acid nanoparticles, also known as nanogels,
which have successfully targeted CD44 receptors in vitro. Poly(d,l lactic-co-glycolic) acid (PLGA)
nanoparticles have also been used with siRNA and have shown significant knockdown of genes
in vivo with less inflammation in comparison to the lipid equivalents. In addition, calcium
carbonate nanoparticles have also shown reduced toxicity with efficacious delivery of siRNA
both in vitro and in vivo. Gold nanoparticles have also been shown to extend siRNA half life
sixfold compared to naked siRNA (4).

17

Limitations also exist for siRNA encapsulated nanoparticles. Nanoparticle aggregation
can occur due to the positive surface charge of the nanoparticles. This can be addressed by
introducing poly(ethylene glycol) (PEG) or certain sugar molecules (cyclodextrin and hyaluronic
acid) to the reduce surface charge. By neurtralizing the surface charge the nanoparticles will be
capable of circulating for longer periods of time and non-specific interactions between the
positively charged nanoparticles and the negative charge of the cell membrane will be
minimized. Targeting the nanoparticles to a specific tissue or cell has also been a problem with
this delivery vector. Modifications to the nanoparticle complex with ligands or antibodies that
recognize specific receptors has helped with this problem. Nanoparticles are also capable of
entering the cell via endocytosis (1). However, for the siRNA to be effective it must be released
from the nanoparticle and endosome to the cytosol in order for the RISC complex to form.
Modifications to the nanopartcle with ligands that specifically target receptors that will mediate
endocytosis can enhance nanoparticle internalization.

Once within the endosome the

nanoparticles must evacuate the endosome to get into the cytosol, which can be achieved by
using polymers that contain protonable amines that are capable of disrupting the endosomal
membrane or by using polymers that transition from hydrophilic to hydrophobic and can lyse
the endosomal membrane. Although methods have been used to address endosomal escape,
new studies have shown that while 90-95% of internalized siRNA nanoparticles occurs via
endocytosis, it is the remaining 5% that enters the cell through alternative pathways that
provides the most functional siRNA within the cytosol (8).
GBM targets for siRNA
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Nanoparticle delivery of siRNA has introduced a new means of gene therapy, however,
finding the appropriate gene target to suppress tumor growth or induce apoptosis has been a
difficult feat.

Identifying an appropriate marker for brain tumors and understanding its

variations and evolutions are important.
Epidermal growth factor receptor gene is a gene commonly found over-expressed in
GBM and is found in about 40% of GBMs patients. Within this population of GBM tumors that
over-express the EGFR, 63-75% of them have rearrangements of the EGFR gene which can
cause tumors to contain wild type EGFR as well as a mutated form. Amongst these mutations
the EGFR variant III, or EGFRvIII, is the most common of the mutated forms and is rarely seen in
normal tissue. This variant is often seen in 20-30% of GBM patients without an overexpression
of EGFR and 50-60% of patients with an overexpression. This mutation often results from a loss
of exons 2 to 7 in the EGFR gene (9).
Type 1 interferon gamma has also shown antitumor activity, however with a short halflife and toxicity occurring with large doses, interferon must be continuously delivered which
increases the likelihood of toxicity.
Research with nanoparticles and GBM
Within the last decade an increasing number of biodegradable polymers have been used
against Glioblastoma Multiforme.

Chemotherapy with cisplatin was added into 6-

carboxylcellulose polymer then infused into post-irradiated patients and was found to be
extend survival to 427.5 days compared to the control group which survived 211.0 days (10).
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A recent Phase I/II clinical trial used CED of a liposomal vector containing the HSV-1-tk
gene with systemic ganciclovir to treat glioblatoma. This treatment was shown to have minimal
side effects and showed a 50% tumor volume reduction in 25% of the treated patients (11).
The copolymer polifeprosan 20 (1,3 bis(p-carboxyphenoxy) propane and sebacic acid in
a 20 to 80 molar ratio with carmustine wafers (Gliadel®) have been shown to have sustained
release for up to five days when placed in a tumor resected cavity (4). The Gliadel wafer spans
14mm in diameter, 1mm in thickness and is loaded with 7.7mg of carmustine. Studies have
shown improved survival of patients with malignant gliomas who received Gliadel either as a
treatment for an initial tumor presentation, recurrence, or as an additional therapy with
radiotherapy. There have however been mixed reports about the affects of Gliadel in regards
to toxicity, inflammation, infection rates in patients (3).

Similar to other wafers, the

chemotherapy released by the Gliadel has relatively poor diffusion throughout the brain. To
resolve this issue smaller drug carrying polymers that are able to perfuse the brain parenchyma
and deliver the chemotherapy can be used. Among the biomaterials that have been used for
this purpose, the copolymer poly(lactide-co-glycolide) has shown the most promise for
delivering drugs and peptides and will be further explored in the experiments of this thesis.

Statement of purpose specific hypothesis and specific aims of the thesis
Hypothesis:
Convection-Enhanced Delivery of siRNA-loaded Polymer Nanoparticles Produces
Effective Gene Knockdown in gliosarcoma tumor cell both in vitro and in vivo.
Specific Aims:
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The goal of these experiments was to develop a new effective delivery method for
treating tumor cells in rats.

Convection-enhanced delivery of siRNA nanoparticles can

introduce a new means of eliminating invasive tumor cells and provide an innovative strategy
for brain cancer treatment. The enhanced green fluorescent protein (EGFP) transfected into
the tumor cells allowed for good visualization of tumor growth and volume quantification after
harvesting the brain tissue.
This project was divided into multiple parts with specific objectives:
The first set of experiments consisted of an in vitro analysis of the growth pattern of
EGFP 9L gliosarcoma cells that were transfected with EGFP via lentiviral vectors, in order to
prove consistent growth patterns between transfected and non-transfected 9L gliosarcoma
cells. The next set of experiments aimed to analyze the efficacy of siRNA knockdown of EGFP
from the 9L gliosarcoma cells in vitro, using lipid vectors and PLGA vectors.
Experiments then looked at the growth rates of 9L gliosarcoma tumor cells with
enhanced green fluorescent protein (EGFP) in Fisher 344 rats in order to establish the in vivo
growth rate of the tumor cells.

Once the untreated tumor cell growth curve had been

established, small interfering enhanced green fluorescent protein (siEGFP) loaded polymer
nanoparticles were infused into growing EGFP tumor cells using the convection-enhanced
delivery method with the aim of determining the effectiveness of CED of nanoparticles in
knocking down gene expression.
The next experiments aimed at identifying a gene within the gliosarcoma cells
that would suppress tumor growth. In vitro studies determined the efficacy of siRNA gene
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knockdown and growth suppression. Nanoparticles loaded with small interfering RNA targeting
epidermal growth factor receptor (EGFR) were used.
Methods
Cell Lines
The 9L rat gliosarcoma cell lines where maintained in a Dulbecco's Modified Eagle
Medium (DMEM) solution that was supplemented with 10% FBS and 1% PenicillinStreptomycin-Fungazone antibiotic.
Cells were split by removing old media and rinsing cells once with 10 mL sterile PBS.
Trypsin EDTA 1X (.25%) was used to detach cells. Additional media was added to the cells and
they were centrifuged with the supernatant disgarded. The cell pellet was then resuspended in
fresh media and added back into a 275 mL flask. Feeding of the cells was done daily. The old
media was removed and 12mL of fresh media was added to each flask. The flasks were then
incubated at 37◦C.
Transfection of 9L gliosarcoma cells
The 9L gliosarcoma cell line was transfected with enhanced green fluorescent protein
(EGFP) using the pSicoR plasmid (addgene©) and lentiviral vectors by Dr. Jiangbing Zhou, a
member of Dr. Mark Saltzman’s lab.
In vitro growth rate analysis
Both the normal 9L cells and EGFP transfected 9L cells were plated in 6-well plates
(5x10^4 cells/well) with 3mL culture media per well. Cells were extracted using trypsin and
counted using a hemocytometer on day 2 and 3.
Production of siRNA PLGA nanoparticles:
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Polylactic-coglycolic acid (PLGA) were loaded with siRNA/polyamines using the doubleemulsion solvent evaporation technique. The siRNA was reconstituted in deionized water. The
polyamine complexes with siRNA where formed at room temperature for 15 minutes on a
rotary shaker. The siRNA (30-300nmoles) was combined with the polyamine at a molar ratio of
the polyamine nitrogen to the polynucleotide phosphate (N/P ratio of 8:1). A molecular weight
per nitrogen of 85g/mole of spermidine was used. The aqueous solution was then added
dropwise to a PLGA polymer solution and dissolved into dicholormethane (2mL) to create the
first emulsion. The emulsion mixture is then added dropwise into 4 mL of 5% polyvinyl alcohol
(PVA) and sonicated to form the double emulsion. This final emulsion was then poured into
aqueous 0.3% (v/v) PVA and stirred for 3 hours, which allows the dicholormethane to dissolve
and the nanoparticles to harden. Sonication time and amplitude were optimized to formulate
particles with 100nm diameter. Particles were then collected by centrifugation, washed,
rapidly frozen, and lyophilized.

The nanoparticles contained 300pmol siRNA/mg of

nanoparticle.
The siRNA sequences used were siEGFP, sense 5’-GGCUACGUCCAGGAGCGCACCdTdT-3’
and antisense 5’-UGCGCUCCUGGACGUAGCCUUdTdT-3’(MW = 14,669.4 g /mol), siEGFR sense
5’-CCGAAUUUAUACACACCAAdTdT-3’, and antisense 5’-UUGGUGUGUAUAAAUUCGGdTdT-3’
(MW = 13,273 g/mol).
Characterization of Nanoparticle size and siRNA loading
In order to determine the loading efficiency of the PLGA nanoparticles, 5mg of
nanoparticles of siRNA nanoparticles were dissolved in 0.5mL of dichloromethane at room
temperature for 30 minutes. The nanoparticles were extracted from the organic phase using
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0.5mL TE buffer (10mM Tris-HCl, 1mM EDTA, pH 7.4). The TE buffer was added to the organic
phase and vortexed for 1 minutes, and then centrifuged at 12,000 rpm for 5 min at 4◦C. The
combined 1 mL aqueous fraction was analyzed for double-stranded RNA content using the
QuantIT™PicoGreen™ assay (Invitrogen). A standard curve relating fluorenscence to siRNA
concentration was used to determine the amount of siRNA in the nanoparticles.
Particle size was determined using the dynamic light scattering (DLS) feature of the
ZetaPals (Brookhaven Instruments) particle size analyzer. Particles were analyzed in a 10μg/mL
in 2mL PBS solution. The particle size was also analyzed using an image analysis of micrographs
from a scanning electron microscopy (SEM). The samples were coated with 25 nm-thick gold
using a quick carbon coater. Using image analysis software the particle diameter and size
distribution was determined.
Nanoparticle Delivery to Cultured Cells
Cells were plated at 3x10^4 to 5x10^4 cells per well in a 6-well tissue culture treated
plate and left to proliferate. After 48 hours in culture, cells were at 30-50% confluence.
Nanoparticle treatment groups and controls were diluted in the DMEM solution with
supplements at a concentration of .1mg/mL for the particles. Cells were exposed to 10nM25μM of siRNA. The treatment groups included siRNA-loaded PLGA nanoparticles, siRNAloaded lipid nanoparticles, a control with no siRNA. Treatment groups were placed on the cells
in 100μL volumes and left for 48, 72, and 120 hours at 37C and 5% CO2. At the end of
incubation, the cells were washed with PBS. Cells were then extracted using trypsin and
evaluated using FACS or RT-PCR.
FACS analysis
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The LSR II Green (BD Biosciences) multilaser multiparameter analysis was utilized. The
digital data collection was done using the FACS DIVA software. The 488nm (blue) detector was
used to identify the GFP fluorescence. Round bottom 12 x 75 mm polystyrene falcon tubes
were used. Cells were extracted and resuspended in 1mL of PBS supplemented with 10% fetal
calf serum (FCS), 1% sodium azide.
RT-PCR
RNA was isolated from the 9L gliosarcoma cells using the RNeasy®Mini Kit (Qiagen)
based on the manufacturer’s protocol. The purified mRNA was reverse transcribed using the
iScript DNA synthesis kit (Biorad) to produce cDNA. Real time PCR was conducted on 2μL of
cDNA combined with the iQ SyBr Green (biorad) reagents for fluorenscent detection of the PCR
product. Primers used for the RT-PCR are: EGFP_forward: 5’- GAAGCGCGATCACATGGT – 3’,
EGFP_reverse: 5’-CCATGCCGAGAGTGATCC-3’. PCR parameters consisted of 5 minute activation
of the DNA polymerase at 95◦C, followed by 40 cycles of expression of 95◦C x 20 s, 60◦C x 30 s,
and 72◦C x 20s.
Implanting tumors in Rat Brain Tissue
The glioma tumor cell line that was used in these experiments were 9L gliosarcoma cells.
These cells induced intracerebral tumors via a craniotomy and using stereotaxis to determine
the injection locations in the brain.
During the surgery the rodents received pre-procedural anesthetic intraperitoneal
injections of ketamine/xyalzine mixture (80/10 mg/kg), followed by an intraperitoneal
analgesic, meloxicam at 0.3 -1.0 mg/mg. Once anesthetized, the scalp of the rodent was
shaved using clippers, and the scalp was sterilized using alcohol and betadine wipes. The
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animal was restrained on a stereotaxic frame, which held the animal in place using two ear bars
and a nose bar. Heart rate and respiratory rate of the animal were monitored manually during
the surgery. These intracranial surgeries took approximately 30 minutes per rat. A midline
incision was made along the scalp using a scalpel. The pericranium was pushed aside and
excess bleeding was wiped off using q-tips until the coronal and sagittal sutures were exposed.
Once the injection coordinates are identified, a burr hole was drilled into the skull going 3.5mm posteriorly and 2.3mm laterally to the right from bregma using a high speed drill. A
sterile needle punctured the dura and a Hamilton syringe was filled with 1.5µl (1.5x105 cells) of
EGFP-labeled 9L gliosarcoma cells suspended in injection buffer (sterile PBS, MgCl 2 (1µg/mL),
CaCl2 (1ug/mL), 0.1% glucose). The needle was inserted 5.7mm deep into the cerebral cortex
and allowed to equilibrate for one minute in the tissue. The needle was withdrawn about
0.2mm and allowed to equilibrate in order to give a space for the cells to fill. The cells were
slowly injected (1.5µl in 1.5mins) into the tissue and given two minutes to settle before the
syringe was removed. The burr hole was plugged with bone wax, and the incision was sutured
or stapled.
Following surgery the animal was then taken to a recovery cage with food and ibuprofen
in drinking water for 48 hours after the surgery. The animal was monitored daily for signs of
pain, discomfort, or abnormal movement or behavior. The incision was checked and cleaned if
necessary.
Animal Maintenance
Fischer 344 rats were used as a model system for this project because of they were large
enough to allow intracranial implantation of polymers of sizes that fall in the range of the
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nanoparticles that were used for these experiments. The rats weighed 180-220 grams. Animals
were housed in Yale Animal Resources Center (YARC) facilities (Malone Engineering Center) and
received the standard care.
Harvesting of Tissue and Growth Analysis
Following tumor implantation, animals were maintained for various amounts of time: 115 days. Animals were euthanized by carbon dioxide overdose according to YARC procedure,
and the brain was removed and frozen directly on dry ice. The brain was then stored in a -80◦C
freezer before sectioning. The brains were sectioned into thin slices of known thickness by a
microtome machine and then fluorescent images were taken of the coronal brain sections. The
tumor showed up as a green image because of the EGFP, and the tumor volume was calculated
from the area of green signal found on each slice and the given width of the slice.
Intracranial implantation of siRNA nanoparticles
The infusion procedure of the nanoparticles utilized convection enhanced delivery and
was the same as the ‘Implanting tumors in Rat Brain Tissue’ procedure with a few alterations. A
nose cone was added to the stereotaxis frame and 1-4% of isoflurane was added to the oxygen
to maintain anesthesia for the longer procedure. The CED technique took longer because the
infusion time and volume of nanoparticles infused (about 20ul) was large. A catheter probe
was used to administer the nanoparticles and fluid into the brain tissue, substituting for the
Hamilton syringe. The nanoparticles were re-suspended in 20μL sterile PBS buffer solution
(supplemented with MgCl2 (1ug/mL), CaCl2 (1ug/mL), 0.1% glucose). A sterile needle was used
to puncture the dura and a syringe with the catheter probe was filled with the suspended
nanoparticles. The probe was then inserted into the right hemisphere of the cerebral cortex,
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just anterior to the putamen for one minute to equilibrate with the tissue. The nanoparticles
were slowly injected (1.5µl in 1.5mins) into the tissue and given two minutes to settle before
the probe was removed. The burr hole was plugged with bone wax, and the incision was
stapled. Typical surgeries took about one hour per animal.
Production of the Lipid nanoparticles
The siRNA was incubated with Lipofectamine™, a cationic lipid, in order to form a lipid
complex that was infused into the brain tumor. Established protocols for this procedure are
available at www.invitrogen.com/RNAiMAX.
Statistical Analysis
Experimental conditions were compared using a two tailed t-test to evaluate whether a
significant difference existed between conditions. P-values less than 0.05 were considered to
be significant.
The PLGA and Lipid nanoparticle conditions were corrected with their respective
controls in the in vivo charts.
All experiments were conducted by the author unless otherwise stated.
Tumor fluorescent volume is a term used in this thesis that refers to the overall
fluorescence generated by the 9L gliosarcoma cells. When exposed to small interfering EGFP
(siEGFP), the actual tumor cell volume
remains unchanged, but the

siEGFP

exposed tumor cells have a lower tumor
fluorescent volume (Figure 1).
Figure 1: A, represents a group of EGFP transfected 9L gliosarcoma
cells that have not been exposed to siEGFP, while B, represents a
group of EGFP transfected 9L gliosarcoma cells after exposure to
siEGFP. Specimen A and B have equal overall tumor volume, but
specimen A has a higher tumor fluorescent volume than specimen
B.
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Results
EGFP transfected cell proliferation assay
30

gliosarcoma passage 5 cells to 9L passage 5 cells that
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were transfected with EGFP with a lentiviral vector
in order to determine whether the transfected cells
had a similar growth rate as the regular cells. On
day two the transfected 9L cells showed a similar

growth rate to the normal 9L cells with the
standardized mean cell count being 9 ±2.2 and 10.1

Standardized Cell Count

A proliferation assay compared regular 9L

20
15
10
5
0
day 0
day 2
day 3
EGFP 9L
Normal 9L

Figure 2: The EGFP transfected 9L
gliosarcoma cells show a similar growth
patterns as a non-transfected 9L gliosarcoma
cells over a three day period. The p-value for
both timepoints was p>0.05

±2.1 respectively (Figure 2). The two tailed t-test showed a p-value of 0.68. The day three time
points of the transfected cells showed a mean standardized cell growth of 18.6 ±2.9 and the
normal 9L cells showed a mean of 22.6 ±3.1. The two tailed t-test showed a p-value of 0.13
(n=3).
Characterization of the siRNA
The PLGA nanoparticles loaded with siEGFP or siEGFR were analyzed by scanning
electron microscopy and dynamic light scattering to characterize the size. The data generated
from the DLS was used to create a histogram to calculate the average diameter of the
nanoparticles. For the siEGFP-loaded PLGA nanoparticles the mean diameter was 110 ±24nm
(n=100). The minimum and maximum diameters were 58.7 and 182.7 nm. This was supported
by the SEM analysis. The histogram of the siEGFR-loaded nanoparticles showed nanoparticles
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with a mean diameter of 109 ±20nm (n=103). The minimum and maximum diameters were
73.6nm and 176.5nm, respectively (Figure 3). The SEM confirms the size of the nanoparticles.
In vitro siRNA nanoparticle knockdown
An in vitro study was conducted that looked at the efficacy of siRNA knockdown of the
EGFP using the PLGA nanoparticles. The EGFP transfected 9L gliosarcoma cells were plated on
6-well plates and exposed to three conditions: siEGFP-loaded PLGA nanoparticles, scrambled
siRNA PLGA nanoparticles, and no nanoparticles. The cells were exposed to 10nM of siRNA
within the nanoparticles. Over a four day period the siEGFP-loaded nanoparticles showed
significant knockdown under visual microscopy. The PLGA nanoparticles with scrambled siRNA
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Figure 3: Top left, scanning electron micrographs (SEM) of the siEGFP nanoparticles prepared using spermidine as a complexing agent.
Top right, histogram of siEGFP-loaded PLGA nanoparticle diameters with a mean value of 110 ±24nm. Bottom left, SEM image of the
siEGFR nanoparticles. Bottom right, histogram depicting the diameters of siEGFR-loaded PLGA with a mean value of 109 ±20nm. Bar =
500nm.
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showed minimal knockdown (Figure 4). FACS and RT-PCR were used to quantify the level of
fluorescence generated from the cells at the three time points (Figure 5). The FACS analysis
showed the siEGFP-loaded nanoparticles were capable of diminishing the majority of the 9L
population fluorescence () and possessed a small population of complete knockdown ().
The RT-PCR analysis looking at the level of EGFP expression showed a

45%

Figure 4: In vitro images
of the enhanced green
fluorescent protein 9L
gliosarcoma cells that
were grown to 30%
confluency and were then
exposed to the siRNA
nanoparticles for three
different timepoints.

green fluorescent reduction by the siEGFP compared to the control on day two. The scrambled
siRNA nanoparticles had no significant difference in the level of fluorescence compared to the
control (p=0.79, n=6). On day 3, the siEGFP reduced fluorescence by 53% compared to the
control. The scrambled siRNA nanoparticles had no significant difference in the level of
fluorescence (p=0.06).

Day 5 results were similar with the siEGFP-loaded nanoparticle

condition showing a 50% EGFP expression reduction and the scrambled siRNA had no significant
EGFP reduction compared to the control (p=0.07).
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Figure 5: Nanoparticles delivering siEGFP are internalized and cause sustained gene silencing in cultured cells, in
vitro. A, FACS analysis shows EGFP expression was reduced in cultured cells exposed to the siEGFP nanoparticles ( )
and a small population showed complete knockdown (). B, RT-PCR results of the siEGFP nanoparticles knockdown
on cultured cells. The * mark is above the bar for the normal 9L cells EGFP expression (n=3).

In vivo 9L EGFP gliosarcoma cell knockdown
The Fischer 344 rats were intracranially injected with 9L gliosarcoma cells which were
allowed to grow for five days. On day 5, either lipid or PLGA nanoparticles were injected
intratumorally and tumor fluorescent growth was analyzed on day 8, 11, and 15 (Figure 6). On
day 8, the siEGFP-loaded PLGA nanoparticles showed significant knockdown of the EGFP
fluorescence, in vivo, with a 60% reduction of the fluorescence (p-value= 0.009, n= 3). The
mean tumor fluorescent volume of the 9L cells exposed to siEGFP-loaded nanoparticles were
3.8±1.6mm3 compared to the control which was 9.6±2.9mm3. The siEGFP-loaded lipofectamine
also showed some EGFP knockdown with a tumor fluorescent volume of 6.7±4.4mm3 (p-value =
0.03, n= 3).

Compared to the lipid nanoparticles, the siEFGP-loaded PLGA nanoparticles

showed 30% more reduction of the 9L cells green fluorescence than the lipid vectors (p-value =
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Figure 5: The Fischer 344 rats were injected with 9L gliosarcoma cells which were allowed to grow in vivo for 5 days.
Nanoparticles (either lipid or PLGA) were injected into the rat brain, intratumorally, on day five and remained in the
brain for an additional three, six, or ten days. The rats were sacrificed and the brain was harvested and cut into
coronal sections. The cells exposed to the siEGFP had various levels of green fluorescent knockdown. A microscope
was used to analyzed the total tumor fluorescent volume.

0.04). On day 11 however the tumor fluorescent volumes showed no significant difference with
the siEGFP-loaded PLGA nanoparticles (p-value = 0.26) and the siEGFP-loaded lipid
nanoparticles (p-value = 0.13) compared to the control. Day 15 showed similar results with the
no tumor fluorescent volume difference with the siEGFP-loaded PLGA nanoparticles (p-value =
0.75) and siEGFP-loaded lipid nanoparticles (p-value = 0.11) (Figure 7).
In vitro knockdown of 9L gliosarcoma cell growth
A gene target capable of suppressing growth of 9L gliosarcoma cells was identified to
test out the knockdown capabilities of siRNA nanoparticles. Epidermal growth factor receptor
gene was the target for siRNA knockdown. Small interfering epidermal growth factor receptor
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Figure 7: A, Day 8 of the in vivo Tumor fluorescent volume. The siEGFP-loaded PLGA nanoparticles (25nM) showed
significant green fluorescent knockdown (p=0.009). The lipid nanoparticles also show significant tumor fluorescent
reduction (p=0.03). B, Day 11 and 15, showed no significant difference in fluorescence compared to the control.

(siEGFR) was encapsulated by PLGA. In addition, nonspecific siRNA (scrambled siRNA) was also
encapsulated in PLGA. The 9L cells were plated on 6 well plates and grown for 48 hours. At
this time the cells were exposed to the siEGFR or scrambled siRNA nanoparticles. Two days
after exposure to the siEGFR significant suppression of growth was seen in the the 9L
gliosarcoma cells with a 66 percent reduction of growth (p value =0.048, n = 3). The scrambled
siRNA did not show any significant suppression of the 9L growth (p value = 0.21, n = 3). Three
days after siRNA exposure, the siEGFR showed an 89 percent reduction of growth compared to
the control (p value= 0.022). The scrambled siRNA did not show any growth suppression (pvalue = 0.32) (Figure 8,9). Time constraints prevented an in vivo study of the effects of siEGFRloaded nanoparticles on 9L cells from being conducted.
Discussion
The reported experiments explored the efficacy of siRNA nanoparticles both in vitro and
in vivo. The EGFP transfected 9L gliosarcoma cells were shown to have consistent growth with
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the normal 9L cells and proved to serve as an adequate tumor cell model for the analysis of the

Figure 8: Microscopic images of 9L gliosarcoma cells after exposure to siEGFR and scrambled siRNA. The siEGFR
reduced the growth of the 9L cells by 66% two days after exposure and 89% three days after. The scrambled siRNA
showed no significant growth reduction.

efficacy of siRNA knockdown. The proliferation analysis showed no significant difference
between the growth rate of the 9L transfected cells compared to the non-transfected cells,
which allowed the green fluorescent transfected cells to be used for growth assessment
studies.
Both the small interfering enhanced green fluorescent protein (siEGFP) and the small
interfering epidermal growth factor receptor (siEGFR) were able to encapsulate into a PLGA
copolymer with a diameter of around 110nm. Although the extracellular space fluid filled pores
in a Fischer 344 rat are around 38-64nm diameter and optimal nanoparticle diffusion within the
rat brain would require a diameter within this range, with the pressure from the convection
enhanced delivery and the particles’ distribution origin starting from within the tumor, the
nanoparticles were still capable of diffusing (12).
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Figure 9: 9L gliosarcoma cells
were plate on 6-well plates and
allowed to grow for 24 hours and
then exposed to siEGFR and
scrambled siRNA nanoparticles.
Two days after exposure to the
siRNA the siEGFR showed
significant suppression of 9L
growth (p=0.048) while the
scrambled siRNA did not
(p=0.21). Day 4 showed a 89%
growth reduction of the siEGFR
condition compared to the
control (p=0.022). (The
scrambled siRNA contained small
interfering enhanced green
fluorescent protein, siEGFP).

In vitro studies of the siEGFP nanoparticle knockdown compared to the control and
scrambled siRNA showed significant knockdown of the green fluorescent signal over a five day
period. The FACS and RT-PCR studies determined that the majority of EGFP transfected 9L
gliosarcoma cells had underwent a significant reduction in green fluorescence, however only a
small population of cells had underwent complete knockdown. The small number of complete
knockdown cells could be indicated by the low concentration (10nm) of siEGFP that was used in
the in vitro studies.
In vivo studies produced similar results as the in vitro study, showing significant
knockdown of the green fluorescence with siEGFP-loaded PLGA nanoparticles. The PLGA
nanoparticles were compared to lipid nanoparticles which have been shown to have efficacious
siRNA delivery capability, however are considered to be neurotoxic (13). Three days following
in vivo exposure of the 9L tumor to siEGFP-loaded PLGA nanoparticles, there was a significant
knockdown compared to both the control and the lipid nanoparticles. The sixty percent green
fluorescent reduction by the siEGFP-loaded PLGA nanoparticles showed that the siRNA as a
drug delivery mechanism has potential of suppressing gene expression with specificity.
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However, at six and ten days following in vivo introduction of the siRNA, the PLGA polymers did
not show any significant knockdown of the EGFP in the 9L cells. Similar to the in vitro studies,
the nanoparticles were likely to not contain a large enough dose of the siEGFP. Loading PLGA
nanoparticles with siRNA has been shown to be difficult and often results in nanoparticles with
low siRNA concentration (14).

Using the common preparation technique of the double

emulsion solvent evaporation method, it is difficult to have a high siRNA loading efficiency. This
is a result of the low molecular weight of the siRNA which allows for the nuclei acid to leak out
of the inner water phase of the nanoparticle into the environmental outer water phase during
the preparation. The hydrophilic nature of the siRNA along with the electrostatic repulsion
forces of the phosphate groups of the nucleic acid and the anionic acid groups of the polymer
causes the siRNA to leak out. This makes it difficult to have high encapsulation efficiency and
causes quick release of the siRNA once it is exposed to the hydrophilic environment, which may
be the cause of the early fluorescent knock down, but no subsequent knock down in the
following timepoints.
Strategies to address this issue might be to change the spermidine complexing agent to
another

cationic

material

such

as

dioleyltrimethylammoniumpropane

(DOTAP)

or

polyethyleneimine which have stronger bonds to siRNA. However, these materials may delay
the release of siRNA.
With evidence of efficacious gene suppression of the green fluorescence in the 9L cells,
the next experiments looked at a gene target that would suppress cellular proliferation. Small
interfering epidermal growth factor receptor (siEGFR) was selected for in vitro studies and
showed significant suppression of cellular growth.
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EGFR has been shown to be present in 40% of Glioblastoma patients and has been
shown to be a viable target for growth suppression. Although only a portion of GBM patients
over express the epidermal growth factor receptor on their cell surface, intracellular EGFR
affects signal transduction cascades, such as the MAPK, Akt, and JNK pathways all which are
involved in DNA synthesis, cellular proliferation, and cell adhesion. The intracellular activity of
the siEGFR may offer additional suppressive effects that extend beyond solely inhibiting the
receptor function on the outer cell surface, however no studies have determined whether
siEGFR may inhibit intracellular transduction cascades integral to cellular proliferation in tumor
cells that do not over express epidermal growth factor receptors.
Although this study showed that suppression of the EGFR gene inhibits growth, new
studies have shown that the deletion of the nuclear factor of K-light polypeptide gene enhancer
in B–cells inhibitor-α (NFKB/A), a gene whose product functions to inhibit EGFR, can cause
tumorigenesis in patients who lack the excessive EGFR activation that is commonly seen in a
portion of GBM patients (15).

It is believed that this mutation in addition to the over

expression of EGFR may represent a majority of GBM patients and provides a new potential
gene to investigate.
The experimental results showed that PLGA delivery of siRNA is capable of gene
knockdown, however the short term duration of suppression requires that additional work
needs to be done to reduce the diameter of the PLGA nanoparticles to a size under 70nm
where the nanoparticles may diffuse through the extracellular space of the brain with less
obstruction. In addition to reducing the size, utilizing different complexing agents that may be
capable of preventing quick leakage of siRNA out of the nanoparticle may also be warranted.
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EGFR has been shown to be a viable gene target for growth suppression, however future
studies using a mixture of many siRNA gene targets within the nanoparticles may provide a
more effective suppression of growth. Additional work will also need to investigate whether
siEGFR has suppressive effects on 9L cells in vivo.
The last decade has seen numerous advancements in the use of siRNA and nanoparticles
as therapeutics for gene silencing. Delivery of siRNA using the PLGA matrix allows for efficient
tumor and brain penetration as well as good cellular uptake, protection of the siRNA from
RNase activity, and an alterable and controllable degradation character that can allow for
specific targeting and sustained release. PLGA is a delivery vector that has shown itself to be
efficacious with in vitro and in vivo delivery of siRNA and may provide the means of effectively
treating brain tumors.
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